



[Sagnik Bhattacharyya](#) is a Professor of Translational Neuroscience & Psychiatry and Deputy Head of the Department of Psychosis Studies at King's College London, and is a Consultant Psychiatrist at the South London & Maudsley NHS foundation trust. Sagnik is ranked number [two](#) worldwide (Expertscape) among biomedical scientists working on cannabis and has been employing experimental medicine approaches in conjunction with neuroimaging and pharmacological challenge to understand the neurophysiological and neurocognitive basis of the effects of cannabis and cannabinoids. His work has provided the first human evidence of the distinct neurophysiological effects of the two major cannabinoids present in cannabis extract, delta-9-tetrahydrocannabinol and Cannabidiol and proof-of-concept evidence that Cannabidiol may have therapeutic potential as an antipsychotic. Sagnik's group is leading randomized clinical trials investigating the efficacy of cannabidiol in different stages of psychosis as well as in neurodegenerative disorders such as Parkinson's disease.